What changed in 2026
Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist. Its U.S. prescribing information records initial approval in 2026 and an indication for reducing excess body weight and maintaining that reduction in adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.
This creates another approved prescription route for adults who want to discuss oral treatment. It does not mean everyone qualifies, that tablets are always preferable to injections, or that the ingredient should be bought from a research-chemical seller. The medicine, its branded formulation and its approved label matter together.
The site’s older content centered on weekly injections and the first oral Wegovy announcement. A current comparison needs to include Foundayo, while keeping its evidence separate from semaglutide and tirzepatide. Each medicine has its own trials, population and dose schedule.
Sources: Foundayo prescribing information
How it differs from oral Wegovy
Foundayo can be taken once daily with or without food. Its label does not impose the fasting, water-volume and waiting-period requirements that apply to Wegovy tablets. That difference may matter if you already take morning medicines or find a fasting routine difficult.
Wegovy tablets contain semaglutide. The label directs patients to take the tablet on an empty stomach in the morning with up to four ounces of water, then wait at least 30 minutes before food, other beverages or other oral medicines. Foundayo contains a different active ingredient. Their tablet strengths are not dose equivalents.
A more convenient administration routine is not proof that one drug produces a better result for an individual. Discuss tolerability, interactions, clinical history, coverage and the ability to follow the routine over time. Do not substitute one oral product for another or use an injection-to-tablet conversion found online.
Sources: Foundayo prescribing information · Wegovy prescribing information
Escalation and interactions require a plan
Foundayo is started at a low dose and increased gradually under the label’s schedule and the prescriber’s direction. Its starting dose is 0.8 mg daily; increases occur after at least 30 days at the current dose. The label gives multiple dose steps and a maximum daily dose. A starting supply is therefore not the same as a maintenance prescription.
Before treatment, provide a complete list of prescriptions, over-the-counter medicines and supplements. Foundayo has important interaction instructions involving CYP3A4 medicines and some other drugs, including a limit on simvastatin when used together. A clinician or pharmacist should review the actual list rather than assume all oral medicines can be taken unchanged.
Its label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase. If pregnancy is possible or planned, discuss this before treatment. The contraception instructions for a different GLP-1 medicine should not be copied onto Foundayo.
Sources: Foundayo prescribing information
Safety questions to bring to the visit
Foundayo has a boxed warning about thyroid C-cell tumors observed in rats; the relevance to humans is not established. It is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and with a known serious hypersensitivity to its ingredients.
The prescribing information also covers gastrointestinal reactions, dehydration-related kidney injury, gallbladder problems, pancreatitis and other precautions. Combining it with insulin or an insulin secretagogue can increase hypoglycemia risk. Review these risks with the person managing your care, especially if another clinician prescribes your diabetes medicines.
The label calls for discontinuing Foundayo when pregnancy is recognized and does not recommend it for nursing women. Discuss pregnancy plans, contraception and breastfeeding before treatment rather than applying the instructions for semaglutide or tirzepatide.
Severe abdominal pain that does not go away can be a pancreatitis warning; the label instructs patients to stop treatment and seek medical help promptly. For trouble breathing or swallowing, face or throat swelling, or collapse suggesting a serious allergic reaction, call 911 or the local emergency number immediately. Persistent vomiting or inability to keep fluids down also needs prompt assessment. Tell the procedure team about treatment before surgery or deep sedation, and keep other treatment changes with the prescriber.
Sources: Foundayo prescribing information · Anaphylaxis: MedlinePlus Medical Encyclopedia
Compare the full access cost
The clinical visit, medication fill and any membership are separate possible expenses. An advertised tablet starting offer may apply only to a low strength, a new patient or a time-limited savings program. Confirm the pharmacy quote for the dose expected after escalation and any conditions attached to the offer.
A provider profile should tell you which product is actually prescribed. A listing for “oral GLP-1” does not establish that the tablet is approved Foundayo or Wegovy. Compounded, dissolvable and sublingual products have separate evidence limitations, and approved-product trial results do not establish their performance.
Keep a record of your prescription, dispensing pharmacy, first payment, renewal amount and clinical follow-up plan. If you are changing medicines or providers, arrange the next clinical review before making a financial commitment so that administrative access and treatment continuity fit together.
Sources: Foundayo prescribing information · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA